FGF1 and cancer: In this study, we determined that RES significantly decreased FGF1-induced cancer cell proliferation as well as unregulated apoptosis, suggesting RES, as an adjuvant drug, could effectively avoid the side effects of FGF1 application, especially in cancer-prone disease.